Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARROW: Once-weekly vs Twice-weekly Carfilzomib in RRMM
NCT02412878Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2015
- Primary completion
- Jun 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 20
01
Overview
A Phase 3 trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Started Sep 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02412878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412878.